The Parkinson's disease-associated gene ITPKB protects against ?-synuclein aggregation by regulating ER-to-mitochondria calcium release.

ABSTRACT: Inositol-1,4,5-triphosphate (IP₃) kinase B (ITPKB) is a ubiquitously expressed lipid kinase that inactivates IP₃, a secondary messenger that stimulates calcium release from the endoplasmic reticulum (ER). Genome-wide association studies have identified common variants in the ITPKB gene locus associated with reduced risk of sporadic Parkinson's disease (PD). Here, we investigate whether ITPKB activity or expression level impacts PD phenotypes in cellular and animal models. In primary neurons, knockdown or pharmacological inhibition of ITPKB increased levels of phosphorylated, insoluble ?-synuclein pathology following treatment with ?-synuclein preformed fibrils (PFFs). Conversely, ITPKB overexpression reduced PFF-induced ?-synuclein aggregation. We also demonstrate that ITPKB inhibition or knockdown increases intracellular calcium levels in neurons, leading to an accumulation of calcium in mitochondria that increases respiration and inhibits the initiation of autophagy, suggesting that ITPKB regulates ?-synuclein pathology by inhibiting ER-to-mitochondria calcium transport. Furthermore, the effects of ITPKB on mitochondrial calcium and respiration were prevented by pretreatment with pharmacological inhibitors of the mitochondrial calcium uniporter complex, which was also sufficient to reduce ?-synuclein pathology in PFF-treated neurons. Taken together, these results identify ITPKB as a negative regulator of ?-synuclein aggregation and highlight modulation of ER-to-mitochondria calcium flux as a therapeutic strategy for the treatment of sporadic PD.

SUBMITTER: Apicco DJ 

PROVIDER: S-EPMC7817155 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature